menu
    • menu

    Company profile for Immunovant

    NEW Drugs in Dev: 4
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We...
    Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Graves’ ophthalmopathy (GO).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunovantUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    IMMUNOVANT, INC. 320 W 37th St, 3rd Fl New York, NY 10018
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immunovant.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/immunovant
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immunovant To Release Q3 2025 Financials And Business Update
    Immunovant To Release Q3 2025 Financials And Business Update

    23 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/23/3225101/0/en/Immunovant-to-Report-Financial-Results-for-the-Third-Quarter-Ended-December-31-2025-and-Provide-Business-Update-on-Friday-February-6-2026.html

    GLOBENEWSWIRE
    23 Jan 2026
    Share Share
    Immunovant Prices $550M Common Stock Financing
    Immunovant Prices $550M Common Stock Financing

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203622/0/en/Immunovant-Announces-Pricing-of-550-Million-Common-Stock-Financing.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Immunovant Updates Corporate Progress And Q2 Financials Update
    Immunovant Updates Corporate Progress And Q2 Financials Update

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184399/0/en/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Second-Quarter-Ended-September-30-2025.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Immunovant To Release Q2 2025 Financials And Business Update
    Immunovant To Release Q2 2025 Financials And Business Update

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174961/0/en/Immunovant-to-Report-Financial-Results-for-the-Second-Quarter-Ended-September-30-2025-and-Provide-Business-Update-on-Monday-November-10-2025.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Immunovant's Corporate Updates and Q2 2025 Financial Results
    Immunovant's Corporate Updates and Q2 2025 Financial Results

    11 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/11/3130764/0/en/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Quarter-Ended-June-30-2025.html

    GLOBENEWSWIRE
    11 Aug 2025
    Share Share
    Immunovant Updates and Reports Q4, Fiscal Year Ended March 31
    Immunovant Updates and Reports Q4, Fiscal Year Ended March 31

    29 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/29/3090173/0/en/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Fourth-Quarter-and-Fiscal-Year-Ended-March-31-2025.html

    GLOBENEWSWIRE
    29 May 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search